🚀 VC round data is live in beta, check it out!
Sawai Group Holdings Valuation Multiples
Discover revenue and EBITDA valuation multiples for Sawai Group Holdings and similar public comparables like MBX Biosciences, Zhejiang Jolly, Damora Therapeutics, Immunocore Holdings and more.
Sawai Group Holdings Overview
About Sawai Group Holdings
Sawai Group Holdings Co Ltd is engaged in providing management support or guidance to domestic and foreign companies engaged in businesses related to medical and healthcare services, such as the manufacture and sale of pharmaceutical products and medical equipment, as well as various businesses incidental or related to the same.
Founded
2021
HQ
Employees
3.1K
Website
Sectors
Financials (LTM)
EV
$2B
Sawai Group Holdings Financials
Sawai Group Holdings reported last 12-month revenue of $1B and EBITDA of $241M.
In the same LTM period, Sawai Group Holdings generated $382M in gross profit, $241M in EBITDA, and $91M in net income.
Revenue (LTM)
Sawai Group Holdings P&L
In the most recent fiscal year, Sawai Group Holdings reported revenue of $1B and EBITDA of $239M.
Sawai Group Holdings expects next 12-month revenue of XXX and NTM EBITDA of XXX
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue | $1B | XXX | $1B | XXX | XXX | XXX |
| Gross Profit | $382M | XXX | $354M | XXX | XXX | XXX |
| Gross Margin | 30% | XXX | 27% | XXX | XXX | XXX |
| EBITDA | $241M | XXX | $239M | XXX | XXX | XXX |
| EBITDA Margin | 19% | XXX | 18% | XXX | XXX | XXX |
| EBIT Margin | 11% | XXX | 11% | XXX | XXX | XXX |
| Net Profit | $91M | XXX | $157M | XXX | XXX | XXX |
| Net Margin | 7% | XXX | 12% | XXX | XXX | XXX |
| Net Debt | — | — | $330M | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
Sawai Group Holdings Stock Performance
Sawai Group Holdings has current market cap of $2B, and enterprise value of $2B.
Market Cap Evolution
Sawai Group Holdings' stock price is $13.87.
| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $2B | $2B | -2.0% | XXX | XXX | XXX | $1.36 |
Benchmark Trading Valuation Multiples by Industry
Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.
Start Free TrialSawai Group Holdings Valuation Multiples
Sawai Group Holdings trades at 1.6x EV/Revenue multiple, and 8.6x EV/EBITDA.
EV / Revenue (LTM)
Sawai Group Holdings Financial Valuation Multiples
As of April 18, 2026, Sawai Group Holdings has market cap of $2B and EV of $2B.
Equity research analysts estimate Sawai Group Holdings' 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Sawai Group Holdings has a P/E ratio of 17.7x.
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $2B | XXX | $2B | XXX | XXX | XXX |
| EV (current) | $2B | XXX | $2B | XXX | XXX | XXX |
| EV/Revenue | 1.6x | XXX | 1.6x | XXX | XXX | XXX |
| EV/EBITDA | 8.6x | XXX | 8.7x | XXX | XXX | XXX |
| EV/EBIT | 14.7x | XXX | 14.6x | XXX | XXX | XXX |
| EV/Gross Profit | 5.4x | XXX | 5.9x | XXX | XXX | XXX |
| P/E | 17.7x | XXX | 10.2x | XXX | XXX | XXX |
| EV/FCF | (881.5x) | XXX | 8.8x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Verified Sawai Group Holdings Valuation Multiples
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.
Sawai Group Holdings Margins & Growth Rates
Sawai Group Holdings' revenue in the last 12 month grew by 7%.
Sawai Group Holdings' revenue per employee in the last FY averaged $0.4M, while opex per employee averaged $0.1M for the same period.
Sawai Group Holdings' rule of 40 is 28% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
Sawai Group Holdings' rule of X is 39% (created by Bessemer, rule of X is another metric to measure SaaS companies, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
Sawai Group Holdings Operational Valuation Multiples
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue Growth | 7% | XXX | (0%) | XXX | XXX | XXX |
| EBITDA Margin | 19% | XXX | 18% | XXX | XXX | XXX |
| EBITDA Growth | 22% | XXX | (0%) | XXX | XXX | XXX |
| Rule of 40 | — | XXX | 28% | XXX | XXX | XXX |
| Bessemer Rule of X | — | XXX | 39% | XXX | XXX | XXX |
| Revenue per Employee | — | XXX | $0.4M | XXX | XXX | XXX |
| Opex per Employee | — | XXX | $0.1M | XXX | XXX | XXX |
| G&A Expenses to Revenue | — | XXX | 11% | XXX | XXX | XXX |
| R&D Expenses to Revenue | 5% | XXX | 7% | XXX | XXX | XXX |
| Opex to Revenue | — | XXX | 17% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Sawai Group Holdings Public Comps
See public comps and valuation multiples for other Biopharmaceuticals comps.
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| LTM | 2026E | 2027E | LTM | 2026E | 2027E | |
| Sawai Group Holdings | XXX | XXX | XXX | XXX | XXX | XXX |
| MBX Biosciences | XXX | XXX | XXX | XXX | XXX | XXX |
| Zhejiang Jolly | XXX | XXX | XXX | XXX | XXX | XXX |
| Damora Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| Immunocore Holdings | XXX | XXX | XXX | XXX | XXX | XXX |
| HBM Holdings | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Sawai Group Holdings M&A Activity
Sawai Group Holdings acquired XXX companies to date.
Last acquisition by Sawai Group Holdings was on XXXXXXXX, XXXXX. Sawai Group Holdings acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Acquisitions by Sawai Group Holdings
| Acquired Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Get Verified M&A Valuation Multiples
Sign up to see revenue and EBITDA valuation multiples for 150K+ M&A deals.
Start Free TrialSawai Group Holdings Investment Activity
Sawai Group Holdings invested in XXX companies to date.
Sawai Group Holdings made its latest investment on XXXXXXXX, XXXXX. Sawai Group Holdings invested in XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Investments by Sawai Group Holdings
| Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples
Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.
Start Free TrialAbout Sawai Group Holdings
| When was Sawai Group Holdings founded? | Sawai Group Holdings was founded in 2021. |
| Where is Sawai Group Holdings headquartered? | Sawai Group Holdings is headquartered in Japan. |
| How many employees does Sawai Group Holdings have? | As of today, Sawai Group Holdings has over 3K employees. |
| Who is the CEO of Sawai Group Holdings? | Sawai Group Holdings' CEO is Mitsuo Sawai. |
| Is Sawai Group Holdings publicly listed? | Yes, Sawai Group Holdings is a public company listed on Tokyo Stock Exchange. |
| What is the stock symbol of Sawai Group Holdings? | Sawai Group Holdings trades under 4887 ticker. |
| When did Sawai Group Holdings go public? | Sawai Group Holdings went public in 2021. |
| Who are competitors of Sawai Group Holdings? | Sawai Group Holdings main competitors are MBX Biosciences, Zhejiang Jolly, Damora Therapeutics, Immunocore Holdings. |
| What is the current market cap of Sawai Group Holdings? | Sawai Group Holdings' current market cap is $2B. |
| What is the current revenue of Sawai Group Holdings? | Sawai Group Holdings' last 12 months revenue is $1B. |
| What is the current revenue growth of Sawai Group Holdings? | Sawai Group Holdings revenue growth (NTM/LTM) is 7%. |
| What is the current EV/Revenue multiple of Sawai Group Holdings? | Current revenue multiple of Sawai Group Holdings is 1.6x. |
| Is Sawai Group Holdings profitable? | Yes, Sawai Group Holdings is EBITDA-positive (as of the last 12 months). |
| What is the current EBITDA of Sawai Group Holdings? | Sawai Group Holdings' last 12 months EBITDA is $241M. |
| What is Sawai Group Holdings' EBITDA margin? | Sawai Group Holdings' last 12 months EBITDA margin is 19%. |
| What is the current EV/EBITDA multiple of Sawai Group Holdings? | Current EBITDA multiple of Sawai Group Holdings is 8.6x. |
| What is the current FCF of Sawai Group Holdings? | Sawai Group Holdings' last 12 months FCF is ($2M). |
| What is Sawai Group Holdings' FCF margin? | Sawai Group Holdings' last 12 months FCF margin is (0%). |
| What is the current EV/FCF multiple of Sawai Group Holdings? | Current FCF multiple of Sawai Group Holdings is (881.5x). |
Start Your
Free Trial Today
Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.